期刊
MOLECULAR ASPECTS OF MEDICINE
卷 88, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.mam.2022.101159
关键词
-
资金
- National Institute of virology and bacteriology (Programme EXCELES) [LX22NPO5103]
- European Union-Next Generation EU
Viral protease inhibitors are crucial in the treatment of chronic viral diseases, as they reduce drug resistance and potential side effects, and various protease inhibitors are routinely used in clinical practice.
Some medically important viruses-including retroviruses, flaviviruses, coronaviruses, and herpesviruses-code for a protease, which is indispensable for viral maturation and pathogenesis. Viral protease inhibitors have become an important class of antiviral drugs. Development of the first-in-class viral protease inhibitor saquinavir, which targets HIV protease, started a new era in the treatment of chronic viral diseases. Combining several drugs that target different steps of the viral life cycle enables use of lower doses of individual drugs (and thereby reduction of potential side effects, which frequently occur during long term therapy) and reduces drug-resistance development. Currently, several HIV and HCV protease inhibitors are routinely used in clinical practice. In addition, a drug including an inhibitor of SARS-CoV-2 main protease, nirmatrelvir (co-administered with a pharmacokinetic booster ritonavir as Paxlovid (R)), was recently authorized for emergency use. This review summarizes the basic features of the proteases of human immunodeficiency virus (HIV), hepatitis C virus (HCV), and SARS-CoV-2 and discusses the properties of their inhibitors in clinical use, as well as development of compounds in the pipeline.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据